Review of Current Landscape of HER2-Directed Tumor-Agnostic Therapies
Panelist discusses how HER2-directed tumor-agnostic therapies represent an emerging treatment paradigm focused on targeting HER2 mutations regardless of cancer type. Current agents such as trastuzumab deruxtecan show promise across multiple tumor types that express HER2, moving beyond traditional cancer-specific approaches. This precision medicine strategy may expand treatment options and improve outcomes for patients with HER2-altered cancers who previously had limited therapeutic choices.
EP: 1.Introduction to HER2-Directed Tumor-Agnostic Approaches
EP: 2.HER2 Key Differences and Current Approaches to Biomarker Testing
EP: 3.Updates and Clinical Implications of DESTINY-Lung02 and DESTINY-Lung03 Trials
EP: 4.Review of Current Landscape of HER2-Directed Tumor-Agnostic Therapies
EP: 5.Influence of DESTINY-PanTumor02 Trials on Trastuzumab Deruxtecan Usage
EP: 6.Future of HER2-Directed Tumor-Agnostic Therapies
Video content above is prompted by the following:
- Briefly review the current landscape of HER2-directed tumor-agnostic therapies. What are potential benefits of tumor-agnostic approaches in improving patient outcomes?
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
